Editas Ebitda from 2010 to 2024

EDIT Stock  USD 2.20  0.01  0.45%   
Editas Medicine EBITDA yearly trend continues to be comparatively stable with very little volatility. EBITDA will likely drop to about -171.3 M in 2024. From the period from 2010 to 2024, Editas Medicine EBITDA quarterly data regression had mean square error of 645.1 T and mean deviation of  60,690,577. View All Fundamentals
 
EBITDA  
First Reported
2014-12-31
Previous Quarter
-70.5 M
Current Value
-60.5 M
Quarterly Volatility
19.1 M
 
Yuan Drop
 
Covid
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 3 M or Selling General Administrative of 57.9 M, as well as many indicators such as Price To Sales Ratio of 9.36, Dividend Yield of 0.0 or PTB Ratio of 2.31. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
  
Check out the analysis of Editas Medicine Correlation against competitors.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Latest Editas Medicine's Ebitda Growth Pattern

Below is the plot of the Ebitda of Editas Medicine over the last few years. It is Editas Medicine's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Editas Ebitda Regression Statistics

Arithmetic Mean(98,950,190)
Coefficient Of Variation(72.71)
Mean Deviation60,690,577
Median(113,399,000)
Standard Deviation71,949,476
Sample Variance5176.7T
Range206.1M
R-Value(0.94)
Mean Square Error645.1T
R-Squared0.88
Slope(15,128,928)
Total Sum of Squares72474.2T

Editas Ebitda History

2024-171.3 M
2023-163.1 M
2022-219.6 M
2021-188.1 M
2020-130.9 M
2019-141.1 M
2018-113.4 M

About Editas Medicine Financial Statements

Editas Medicine shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-163.1 M-171.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.